{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:19Z","timestamp":1790263159297,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:00:00Z","timestamp":1543017600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherche sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/jac\/dky467","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T23:21:52Z","timestamp":1540423312000},"page":"739-745","source":"Crossref","is-referenced-by-count":75,"title":["Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)"],"prefix":"10.1093","volume":"74","author":[{"given":"V\u00e9ronique","family":"Joly","sequence":"first","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, SMIT, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Burdet","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, D\u00e9partement d\u2019\u00e9pid\u00e9miologie, Biostatistique et Recherche Clinique, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"IMEA, Fondation L\u00e9on M'BA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vigan","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, D\u00e9partement d\u2019\u00e9pid\u00e9miologie, Biostatistique et Recherche Clinique, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"SMIT, H\u00f4pital La Piti\u00e9 Salp\u00e9tri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Cabi\u00e9","sequence":"additional","affiliation":[{"name":"CIC1424 INSERM, Universit\u00e9 des Antilles, SMIT, CHU de Martinique, Fort de France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Benalycherif","sequence":"additional","affiliation":[{"name":"IMEA, Fondation L\u00e9on M'BA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yeni","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, SMIT, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentre","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, D\u00e9partement d\u2019\u00e9pid\u00e9miologie, Biostatistique et Recherche Clinique, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Argoud","sequence":"additional","affiliation":[{"name":"French Agency for Research on AIDS and Viral Hepatitis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Amri","sequence":"additional","affiliation":[{"name":"French Agency for Research on AIDS and Viral Hepatitis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, SMIT, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LAMIDOL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Marie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jacomet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Cabi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boutouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Reliquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hughes","family":"Aumaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Souala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Biezunski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Ajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Miailhes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Benalicherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babacar","family":"Sylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"2019050711592359200_dky467-B1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/cid\/cir673","article-title":"HIV infection, immune suppression and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users","volume":"53","author":"Salter","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019050711592359200_dky467-B2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"2019050711592359200_dky467-B3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"2019050711592359200_dky467-B4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2019050711592359200_dky467-B5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2019050711592359200_dky467-B6","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2019050711592359200_dky467-B7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000000519","article-title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-na\u00efve HIV-infected individuals in three randomized trials","volume":"29","author":"Raffi","year":"2015","journal-title":"AIDS"},{"key":"2019050711592359200_dky467-B8","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2352-3018(16)30015-7","article-title":"Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis","volume":"3","author":"Achhra","year":"2016","journal-title":"Lancet HIV"},{"key":"2019050711592359200_dky467-B9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2019050711592359200_dky467-B10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2019050711592359200_dky467-B11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG 5353: a pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1 infected participants with HIV-1 RNA <500,000 copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019050711592359200_dky467-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2019050711592359200_dky467-B13","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintain human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019050711592359200_dky467-B14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr BMC"},{"key":"2019050711592359200_dky467-B15","author":"Song"},{"key":"2019050711592359200_dky467-B16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIVIING): a p-48 week, randomized, non-inferiority, open-label, phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir Ther"},{"key":"2019050711592359200_dky467-B17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"2019050711592359200_dky467-B18","doi-asserted-by":"crossref","first-page":"21678.","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-na\u00efve patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2019050711592359200_dky467-B19","author":"Reynes"},{"key":"2019050711592359200_dky467-B20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1310\/hct1401-10","article-title":"Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants","volume":"14","author":"Gutierrez","year":"2013","journal-title":"HIV Clin Trials"},{"key":"2019050711592359200_dky467-B21","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (Domono): a phase 2, randomized, non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"2019050711592359200_dky467-B22","first-page":"237","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume-title":"Curr Opin Infect Dis","author":"Blanco","year":"2018"},{"key":"2019050711592359200_dky467-B23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cis1203","article-title":"SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine\/tenofovir from lamivudine\/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen","volume":"56","author":"Campo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019050711592359200_dky467-B24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/phar.1386","article-title":"Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV","volume":"34","author":"Shah","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2019050711592359200_dky467-B25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV-infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019050711592359200_dky467-B26","doi-asserted-by":"crossref","first-page":"20504.","DOI":"10.7448\/IAS.19.1.20504","article-title":"Choice of antiretroviral drugs for continuing treatment scale-up in a public health approach: what more do we need to know?","volume":"19","author":"Vitoria","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2019050711592359200_dky467-B27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12440","article-title":"Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)- containing regimens","volume":"17","author":"Raffi","year":"2016","journal-title":"HIV Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/3\/739\/28565879\/dky467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T18:54:30Z","timestamp":1557255270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/3\/739\/5203400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,23]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky467","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,23]]}}}